Could a single infusion of modified immune cells tame lupus?

NCT ID NCT06121297

First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 39 times

Summary

This early-stage trial is testing a treatment called CABA-201 for people with active systemic lupus erythematosus (SLE), including those with lupus nephritis. CABA-201 is made from a patient's own immune cells, which are modified to target and temporarily remove B cells—a key driver of lupus. The study will enroll 28 adults aged 18 to 65 to check safety and see if this approach can calm the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Boston Children's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact

  • Clinica Universitaria de Navarra

    RECRUITING

    Pamplona, Navarre, 31008, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Columbia University Irving Medical Center

    WITHDRAWN

    New York, New York, 10032, United States

  • Emory University

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Maisonneuve-Rosemont Hospital

    RECRUITING

    Montreal, Quebec, H1T 2M4, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic

    RECRUITING

    Jacksonville, Florida, 32224, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Medical University of South Carolina

    RECRUITING

    Charleston, South Carolina, 29425, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Northwestern Memorial Hospital

    RECRUITING

    Chicago, Illinois, 60611, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The University of Chicago Medical Center

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Tufts Medical Center

    RECRUITING

    Boston, Massachusetts, 02111, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UC Davis Health

    RECRUITING

    Sacramento, California, 95817, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UMass Memorial Hospital

    RECRUITING

    Worcester, Massachusetts, 01655, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • UNC Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California Irvine

    RECRUITING

    Orange, California, 92868, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Florida Health

    ACTIVE_NOT_RECRUITING

    Gainesville, Florida, 32610, United States

  • University of Kansas Medical Center

    RECRUITING

    Kansas City, Kansas, 66160, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55414, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Rochester

    RECRUITING

    Rochester, New York, 14642, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Yale University

    RECRUITING

    New Haven, Connecticut, 06520, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CABA-201 (a type of CAR-T cell therapy made from the patient's own immune cells)

What this could lead to

If it works, this could offer a new way to control lupus by temporarily resetting the immune system, potentially reducing the need for lifelong medications.

What could go wrong

This is an early-phase trial with only 28 participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome and infections.

Conditions

The condition(s) this trial relates to.

autoimmune disease lupus nephritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.